TB Drug Discovery Initiative

To cure TB requires a regimen of several medicines that must be taken daily for six to nine months. But many patients fail to complete the treatment, or medication is incorrectly prescribed, which can lead to multidrug-resistant tuberculosis (MDR-TB).

TB Drug Discovery Initiative

The battle against TB requires new, faster-acting medicines at affordable prices. The Lilly TB Drug Discovery Initiative, launched in June 2007, is a nonprofit public/private partnership focused on accelerating early-stage TB drug discovery. The initiative is run from a research facility in Seattle, Washington, and operates in partnership with the Infectious Disease Research Institute, MSD, and the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health. Bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries, the initiative has a primary goal of filling the pipeline with new clinical candidates for future TB drug development.

Tackling MDR-TB has proven challenging. Less than one percent of estimated MDR-TB patients globally receive appropriate treatment. Over the past eight years, Lilly has learned a lot about the myriad obstacles blocking patient access to diagnosis and treatment. The strategy of transferring technology has proved especially timely, as we realize now that the need for medicines is much greater than anyone imagined when we first began.

Removing barriers will take a focused, coordinated effort by everyone committed to stamping out TB. Success depends on a sustained, joint commitment by governments, NGOs, and businesses to bring an end to this disease.

Partnership objectives:

  • Accelerate early-stage drug discovery for the treatment of TB and MDR-TB.
  • Inspire collaboration between specialists from around the world for the systematic exploration of vast, private molecular libraries in search of new TB treatments.


  • Eli Lilly and Company

    Independent/None, Goods Supplier
    United States | Staff size: 10,000+

    Eli Lilly and Company, incorporated in 1901, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health...

  • Management Sciences for Development (MSD)

    Development Consulting
    United States | Staff size: Unknown

    Management Sciences for Development (MSD) is an international development consulting firm committed to help build strong justice sectors to support a culture of respect for the rule of...

  • Infectious Disease Research Institute (IDRI)

    United States | Staff size: 101-250

    Devastating infectious diseases cause suffering and death for millions of people around the globe. For many years, most of the investment in addressing these global health challenges was focused...

  • Jubilant Biosys

    Goods Supplier, Service Providers
    Staff size: 251-500

    Jubilant Biosys Ltd, Bangalore is an integrated discovery collaborator to major pharmaceutical and biotech companies, accelerating global discovery efforts across multiple therapeutic areas....

  • Center for Infectious Disease Research

    Goods Supplier, Service Providers, Institute
    United States | Staff size: 251-500

    At the Center for Infectious Disease Research (formerly Seattle BioMed), their mission is to make transformative scientific advancements that lead to the prevention and treatment of infectious...

  • Summit plc

    Staff size: Unknown
  • National Institutes of Health (NIH) - United States

    Funding Agencies, Institute
    United States | Staff size: 10,000+

    The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency—making important medical discoveries that...

  • Yourencore

    Service Providers
    United States | Staff size: 101-250

More Resources

Key Information

LocationSouth Asia, North America, India, United States
  • Start Date 2007